Type-specific Neutralization of the Human Immunodeficiency Virus with Antibodies to Env-encoded Synthetic Peptides

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1988 Mar 1

PMID 2450351

Citations 192

Authors

T J Palker

M E Clark

A J Langlois

T J Matthews

K J Weinhold

R R Randall

D P Bolognesi

B F Haynes

Affiliations

Soon will be listed here.

Abstract

A synthetic peptide (SP-10-IIIB) with an amino acid sequence [Cys-Thr-Arg-Pro-Asn-Asn-Asn-Thr-Arg-Lys-Ser-Ile-Arg-Ile-Gln-Arg-Gly-Pro -Pro-Gly-(Tyr); amino acids 303-321] from the human immunodeficiency virus (HIV) isolate human T-cell lymphotropic virus type III (HTLV-III) HTLV-IIIB envelope glycoprotein gp120 was coupled to tetanus toxoid and used to raise goat antibodies to HIV gp120. Goat anti-SP-10-IIIB serum bound to the surface of HTLV-IIIB-infected CEM T cells but not to the surface of HTLV-IIIRF-infected or uninfected CEM T cells. Anti-SP-10-IIIB antibodies also selectively bound to gp120 from lysates of HTLV-IIIB cells in immunoblot assays. Twenty-one percent of sera (28 of 175) from patients seropositive for HIV contained antibodies that reacted with SP-10-IIIB in RIA. Human anti-SP-10-IIIB antibodies affinity purified from acquired immunodeficiency syndrome (AIDS) patient serum bound to HTLV-IIIB-infected cells and immunoprecipitated gp120. Goat antibodies to SP-10-IIIB neutralized HTLV-IIIB (80% neutralization titer of 1/600), inhibited HTLV-IIIB-induced syncytium formation, but did not neutralize HIV isolates HTLV-IIIRF or HTLV-IIIMN or inhibit syncytium formation with these isolates. Also, goat antiserum to an homologous synthetic peptide [SP-10-IIIRF(A), (Cys)-Arg-Lys-Ser-Ile-Thr-Lys-Gly-Pro-Gly-Arg-Val-Ile-Tyr] from gp120 of HIV isolate HTLV-IIIRF inhibited syncytium formation by HTLV-IIIRF, but did not inhibit syncytium formation by HTLV-IIIB or by HTLV-IIIMN. Thus, the amino acid sequences of SP-10-IIIB and SP-10-IIIRF(A) define homologous regions of gp120 that are important in type-specific virus neutralization. The identification of these type-specific neutralizing epitopes should facilitate the design of a polyvalent, synthetic vaccine for AIDS.

Citing Articles

Peptide-Based Vaccination for Antibody Responses Against HIV.

Combadiere B, Beaujean M, Chaudesaigues C, Vieillard V Vaccines (Basel). 2019; 7(3).

PMID: 31480779 PMC: 6789779. DOI: 10.3390/vaccines7030105.

Survivors Remorse: antibody-mediated protection against HIV-1.

Lewis G, Pazgier M, DeVico A Immunol Rev. 2017; 275(1):271-284.

PMID: 28133809 PMC: 5642910. DOI: 10.1111/imr.12510.

The quest for an antibody-based HIV vaccine.

Haynes B, Mascola J Immunol Rev. 2017; 275(1):5-10.

PMID: 28133795 PMC: 5384259. DOI: 10.1111/imr.12517.

In silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells.

Yokoyama M, Nomaguchi M, Doi N, Kanda T, Adachi A, Sato H Front Microbiol. 2016; 7:110.

PMID: 26903989 PMC: 4746247. DOI: 10.3389/fmicb.2016.00110.

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.

Zolla-Pazner S, deCamp A, B Gilbert P, Williams C, Yates N, Williams W PLoS One. 2014; 9(2):e87572.

PMID: 24504509 PMC: 3913641. DOI: 10.1371/journal.pone.0087572.

References

Lasky L, Nakamura G, Smith D, Fennie C, Shimasaki C, Patzer E . Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell. 1987; 50(6):975-85. DOI: 10.1016/0092-8674(87)90524-1. View

Matthews T, Langlois A, Robey W, Chang N, Gallo R, Fischinger P . Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A. 1986; 83(24):9709-13. PMC: 387210. DOI: 10.1073/pnas.83.24.9709. View

Starcich B, Hahn B, Shaw G, McNeely P, Modrow S, Wolf H . Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell. 1986; 45(5):637-48. DOI: 10.1016/0092-8674(86)90778-6. View

Chanh T, Dreesman G, Kanda P, Linette G, Sparrow J, Ho D . Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 1986; 5(11):3065-71. PMC: 1167262. DOI: 10.1002/j.1460-2075.1986.tb04607.x. View

Levy J, Hoffman A, Kramer S, Landis J, Shimabukuro J, Oshiro L . Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science. 1984; 225(4664):840-2. DOI: 10.1126/science.6206563. View

Cease K, Margalit H, Cornette J, Putney S, Robey W, Ouyang C . Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci U S A. 1987; 84(12):4249-53. PMC: 305062. DOI: 10.1073/pnas.84.12.4249. View

Ratner L, Haseltine W, Patarca R, Livak K, Starcich B, Josephs S . Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature. 1985; 313(6000):277-84. DOI: 10.1038/313277a0. View

Kennedy R, Dreesman G, Chanh T, Boswell R, Allan J, Lee T . Use of a resin-bound synthetic peptide for identifying a neutralizing antigenic determinant associated with the human immunodeficiency virus envelope. J Biol Chem. 1987; 262(12):5769-74. View

Alizon M, Wain-Hobson S, Montagnier L, Sonigo P . Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell. 1986; 46(1):63-74. DOI: 10.1016/0092-8674(86)90860-3. View

10.

Popovic M, Sarngadharan M, Read E, Gallo R . Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984; 224(4648):497-500. DOI: 10.1126/science.6200935. View

11.

Weiss R, Clapham P, Weber J, Dalgleish A, Lasky L, BERMAN P . Variable and conserved neutralization antigens of human immunodeficiency virus. Nature. 1986; 324(6097):572-5. DOI: 10.1038/324572a0. View

12.

Palker T, Matthews T, Clark M, Cianciolo G, Randall R, Langlois A . A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. Proc Natl Acad Sci U S A. 1987; 84(8):2479-83. PMC: 304675. DOI: 10.1073/pnas.84.8.2479. View

13.

Sodroski J, Goh W, Rosen C, Campbell K, Haseltine W . Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature. 1986; 322(6078):470-4. DOI: 10.1038/322470a0. View

14.

Dalgleish A, Beverley P, Clapham P, Crawford D, Greaves M, Weiss R . The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984; 312(5996):763-7. DOI: 10.1038/312763a0. View

15.

Barre-Sinoussi F, Chermann J, Rey F, Nugeyre M, Chamaret S, Gruest J . Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983; 220(4599):868-71. DOI: 10.1126/science.6189183. View

16.

Chou P, Fasman G . Conformational parameters for amino acids in helical, beta-sheet, and random coil regions calculated from proteins. Biochemistry. 1974; 13(2):211-22. DOI: 10.1021/bi00699a001. View

17.

Wong-Staal F, Shaw G, Hahn B, Salahuddin S, Popovic M, Markham P . Genomic diversity of human T-lymphotropic virus type III (HTLV-III). Science. 1985; 229(4715):759-62. DOI: 10.1126/science.2992084. View

18.

Ho D, Sarngadharan M, Hirsch M, Schooley R, ROTA T, Kennedy R . Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol. 1987; 61(6):2024-8. PMC: 254212. DOI: 10.1128/JVI.61.6.2024-2028.1987. View

19.

Green N, Alexander H, Olson A, Alexander S, Shinnick T, Sutcliffe J . Immunogenic structure of the influenza virus hemagglutinin. Cell. 1982; 28(3):477-87. DOI: 10.1016/0092-8674(82)90202-1. View

20.

Lifson J, Reyes G, McGrath M, Stein B, Engleman E . AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen. Science. 1986; 232(4754):1123-7. DOI: 10.1126/science.3010463. View